Leqembi became the first Alzheimer’s drug approved to actually slow disease progression rather than merely mask symptoms, and yet more than three years after its initial FDA approval, the debate over whether it represents a genuine breakthrough or an overhyped disappointment has only intensified. The drug slows cognitive decline by roughly 27% compared to placebo — a number that translates to buying patients approximately 5.3 extra months before their condition worsens to the next stage. For a disease that steals minds over the course of years, that margin has left families, physicians, and even entire national health agencies divided on whether the tradeoff is worth it.
European regulators initially rejected Leqembi outright, concluding the benefits did not outweigh the risks, before reversing course months later with tighter restrictions on who could receive it. The controversy is not about one single flaw. It is a collision of modest clinical gains, serious safety risks including brain swelling and bleeding, staggering costs that can exceed $82,000 per year, and a fundamental scientific question about whether clearing amyloid plaques from the brain is even the right strategy. This article examines why each of these factors continues to fuel disagreement, what the latest developments in 2025 and 2026 mean for patients and caregivers, how international regulators have reached starkly different conclusions about the same data, and what the expanding pipeline of newer Alzheimer’s drugs might mean for the future of treatment.
Table of Contents
- What Makes Leqembi’s Benefit So Controversial Among Alzheimer’s Experts?
- How Dangerous Are the Side Effects of Leqembi and Other Anti-Amyloid Drugs?
- Why Did European and American Regulators Reach Opposite Conclusions?
- What Does Leqembi Actually Cost Patients and the Healthcare System?
- What Are the Risks of Relying Too Heavily on the Amyloid Hypothesis?
- How the Subcutaneous Formulation Could Change the Treatment Landscape
- What Comes Next in Alzheimer’s Drug Development?
- Conclusion
- Frequently Asked Questions
What Makes Leqembi’s Benefit So Controversial Among Alzheimer’s Experts?
The central tension around Leqembi, known generically as lecanemab-irmb, comes down to a gap between statistical significance and clinical meaning. In the 18-month Phase 3 Clarity AD trial, patients receiving the drug declined more slowly on a cognitive scale than those on placebo, and the difference was real in a mathematical sense. But a 27% slowing of decline, while encouraging on a graph, can be nearly invisible in a living room. Many clinicians have pointed out that patients and their caregivers may not notice a meaningful difference in day-to-day functioning over an 18-month window. A person with early Alzheimer’s who forgets their grandchild’s name in December instead of July has gained something — but whether that something justifies the cost, risk, and burden of treatment is a deeply personal and deeply contested question. Supporters, including the Alzheimer’s Association, counter that this framing misses the point.
They argue Leqembi is a proof of concept, the first therapy to demonstrate that removing amyloid beta plaques from the brain can alter the trajectory of the disease. After decades of failed Alzheimer’s drug trials, even a modest effect validates the amyloid hypothesis and opens the door for second- and third-generation treatments that may work better. The comparison they draw is to the earliest cancer immunotherapies, which offered small survival gains before the field matured into transformative treatments. What complicates the debate further is the limited duration of published clinical trial data. Only 18 months of controlled trial results exist, and while 3-year open-label extension data presented at the Alzheimer’s Association International Conference in 2024 showed continued benefit with ongoing treatment, open-label extensions lack the rigor of placebo-controlled studies. Patients and physicians are being asked to commit to a demanding treatment regimen based on a relatively thin evidence window for a disease that unfolds over a decade or more.
How Dangerous Are the Side Effects of Leqembi and Other Anti-Amyloid Drugs?
The safety profile of Leqembi is where the controversy sharpens from academic disagreement into urgent clinical concern. The primary risk is a class of side effects called Amyloid-Related Imaging Abnormalities, or ARIA, which manifests as brain swelling (ARIA-E) and microbleeds or superficial iron deposits in the brain (ARIA-H). In the Phase 3 trial, 21.3% of patients receiving Leqembi experienced ARIA compared to 9.3% on placebo. Breaking that down further, 13% of Leqembi patients developed brain swelling versus 2% on placebo, and 17% experienced brain hemorrhages compared to 9% on placebo. Most ARIA cases were detected on routine MRI monitoring and resolved without symptoms, but symptomatic ARIA occurred in 3% of patients, and serious ARIA — the kind that required hospitalization or caused lasting harm — in 0.7%. The deaths that occurred during and after the trial have drawn particular scrutiny. Of 24 total deaths across the core study and open-label extension, three were due to intracerebral hemorrhage: one in the placebo group and two in patients receiving lecanemab.
Four deaths in the extension phase were deemed “possibly related” to treatment. These numbers are small in absolute terms, but they land differently when the drug‘s benefit is itself modest. For a therapy that delays cognitive decline by roughly five months, a nonzero risk of fatal brain bleeding is a harder sell than it would be for a drug that halted the disease entirely. However, not every patient carries the same risk. Individuals who carry two copies of the ApoE4 gene — a known genetic risk factor for Alzheimer’s — face significantly elevated ARIA rates. This is why the European Medicines Agency, when it eventually approved Leqembi in November 2024 after initially rejecting it, restricted the drug to patients with one or no copies of ApoE4. If you or a family member is considering this treatment, genetic testing is not optional — it is a critical safety gate. Patients on blood thinners or with a history of stroke face compounding risks that may tip the calculus further against treatment.
Why Did European and American Regulators Reach Opposite Conclusions?
Perhaps nothing illustrates the depth of the controversy more clearly than the divergent regulatory decisions across the Atlantic. The FDA granted Leqembi accelerated approval in January 2023 and converted it to full traditional approval by July 2023, making the United States the first country to fully endorse the drug. The European Medicines Agency took the same clinical trial data and reached the opposite conclusion, rejecting Leqembi in July 2024 on the grounds that its benefits “do not counterbalance the risk of serious adverse events.” The EMA’s Committee for Medicinal Products for Human Use essentially answered the core question — is a roughly 27% slowing of decline worth a roughly 21% ARIA risk? — with a no. Then the story took another turn. Eisai appealed the decision, and by November 2024 the EMA reversed course and approved Leqembi, but with a significant restriction: only patients with one or no copies of the ApoE4 gene would be eligible.
This compromise acknowledged the validity of the safety concerns while allowing lower-risk patients access to the drug. The EMA followed a similar pattern with Eli Lilly’s Kisunla (donanemab), the second anti-amyloid drug in this class, initially rejecting it in March 2025 before recommending approval in July 2025 after re-examination. The United Kingdom added yet another layer. The National Institute for Health and Care Excellence approved lecanemab but declined to make it available on the National Health Service, citing cost-effectiveness concerns. In practical terms, this means the drug is recognized as legitimate medicine in the UK but most patients cannot actually get it through their public healthcare system. Each of these decisions reflects a different institutional philosophy about how much uncertainty is acceptable when approving treatments for devastating diseases — and none of them is clearly wrong.
What Does Leqembi Actually Cost Patients and the Healthcare System?
The financial dimension of this controversy is enormous and often underappreciated. Leqembi carries an annual list price of approximately $26,500 for the drug itself, but that figure dramatically understates the true cost of treatment. When you factor in the required genetic testing to assess ApoE4 status, regular MRI brain scans to monitor for ARIA (typically every few months), biweekly intravenous infusion sessions at a medical facility, specialist consultations, and other ancillary care, the total estimated treatment cost runs to approximately $82,500 per year per patient. In the United States, where the vast majority of Alzheimer’s patients are over 65, the bulk of this cost falls on Medicare — which is to say, on taxpayers. The cost-per-outcome ratio is where the math becomes particularly uncomfortable. If Leqembi delivers roughly 5.3 months of delayed cognitive decline over 18 months of treatment, and the total cost over that period approaches $125,000 or more, the system is spending a staggering sum for a benefit that may not be perceptible to the patient or their family.
Compare this to treatments for other chronic diseases: a year of statins costs hundreds of dollars and dramatically reduces heart attack risk; insulin, while controversially expensive in the U.S., delivers an unambiguous and life-sustaining benefit. Leqembi occupies a far more uncomfortable position on the value spectrum. This does not mean the drug should not exist or that no patient should receive it. But it does mean that scaling this treatment to the millions of Americans with early Alzheimer’s disease, as some advocates envision, would impose costs that could strain even the U.S. healthcare system. The treatment also demands significant time and logistical commitment — biweekly IV infusions for at least 18 months require reliable transportation, caregiver support, and access to infusion centers that many rural patients simply do not have.
What Are the Risks of Relying Too Heavily on the Amyloid Hypothesis?
Underlying the entire Leqembi debate is a deeper scientific controversy that predates the drug itself: whether amyloid plaques are truly the primary driver of Alzheimer’s disease or merely one of many contributors. The amyloid hypothesis has dominated Alzheimer’s research for over three decades, attracting the lion’s share of funding and drug development effort. Leqembi and Kisunla both work by clearing amyloid beta from the brain, and the fact that doing so produces only modest clinical improvement has reinvigorated critics who argue the field has been too narrowly focused. The concern is not purely academic. If amyloid clearance is necessary but not sufficient to stop Alzheimer’s, then billions of dollars and years of research time have been concentrated on a strategy that will, at best, deliver incremental gains.
Meanwhile, other potential targets — tau protein tangles, neuroinflammation, metabolic dysfunction, vascular factors — may have been underfunded. The 2025 Alzheimer’s drug pipeline includes 182 trials and 138 novel drugs, and while many still target amyloid, newer candidates are beginning to explore these alternative mechanisms. However, dismissing the amyloid approach entirely would be premature. The 3-year open-label extension data for Leqembi showed continued benefit with ongoing treatment, suggesting that sustained plaque clearance may compound over time in ways that an 18-month snapshot cannot capture. Newer drugs like trontinemab have shown amyloid clearance in over 90% of patients with potentially fewer side effects, hinting that the problem may not be the amyloid target itself but rather the tools being used to hit it. If third-generation anti-amyloid therapies can deliver stronger benefits with a safer profile, the current generation of drugs may eventually be seen as crude but directionally correct first attempts.
How the Subcutaneous Formulation Could Change the Treatment Landscape
One of the most significant recent developments is the August 2025 FDA approval of Leqembi Iqlik, a subcutaneous autoinjector that delivers a 360 mg maintenance dose in approximately 15 seconds. Unlike the biweekly IV infusions that require a visit to a medical facility and carry a 26% rate of infusion-related reactions, the autoinjector can be administered at home with systemic reaction rates below 1%. For patients and caregivers already managing the exhausting logistics of dementia care, eliminating regular infusion center visits is a practical improvement that could meaningfully change the treatment burden equation.
In March 2026, the FDA accepted a supplemental application to use the subcutaneous autoinjector not just for maintenance dosing but as a starting dose as well, with Priority Review and a target action date of May 24, 2026. If approved, Leqembi would become the first anti-amyloid treatment offering at-home injection for both initiation and maintenance therapy. A similar application was accepted in China in early 2026. This shift from hospital-based IV infusions to at-home injections does not resolve the questions about efficacy or ARIA risk, but it removes one of the more practical objections to the treatment and could expand access to patients in areas far from specialized infusion centers.
What Comes Next in Alzheimer’s Drug Development?
The current generation of anti-amyloid drugs may be best understood not as endpoints but as opening arguments in a much longer scientific conversation. The 2025 Alzheimer’s drug pipeline, with 182 active trials and 138 novel drugs under investigation, is the largest and most diverse the field has ever seen. Among the most closely watched candidates is trontinemab, which has demonstrated amyloid clearance in more than 90% of treated patients with a potentially improved safety profile compared to lecanemab and donanemab. If these next-generation therapies deliver stronger efficacy with fewer ARIA events, the risk-benefit calculus that has made Leqembi so divisive could shift dramatically.
The broader trajectory points toward combination approaches — targeting amyloid alongside tau, inflammation, or other mechanisms — and toward earlier intervention, potentially treating patients before symptoms appear based on biomarker screening. For families navigating Alzheimer’s today, the honest answer is that the current drugs are imperfect tools for an imperfectly understood disease. They represent genuine scientific progress, but progress that comes packaged with real risks, high costs, and benefits that remain modest by any honest measure. The hope is not that Leqembi will be the answer, but that it cracked a door that better treatments will eventually walk through.
Conclusion
The controversy around Leqembi is not going to resolve cleanly because it reflects genuine, legitimate disagreements about how to weigh uncertain benefits against known risks. A 27% slowing of cognitive decline is not nothing — for some families, five additional months of a loved one recognizing their grandchildren is beyond price. But a 21% rate of brain swelling and bleeding, a cost exceeding $82,000 per year, and the logistical burden of ongoing treatment are also not nothing, particularly when the disease will ultimately progress regardless.
The divergent decisions by the FDA, EMA, and NICE reflect the honest difficulty of making population-level judgments about a deeply individual disease. For patients and caregivers weighing this decision right now, the most important steps are concrete: get ApoE4 genetic testing to understand your personal risk profile, have a frank conversation with a neurologist about whether your stage of disease and overall health make you a reasonable candidate, and understand that the treatment commitment is substantial. The Alzheimer’s drug landscape is evolving rapidly, with newer formulations reducing treatment burden and next-generation therapies in the pipeline that may offer better results. This is a field where the right answer in 2026 may not be the right answer in 2028, and staying informed matters as much as any single treatment decision.
Frequently Asked Questions
Is Leqembi a cure for Alzheimer’s disease?
No. Leqembi does not cure, stop, or reverse Alzheimer’s disease. In clinical trials, it slowed cognitive decline by approximately 27% compared to placebo over 18 months, which translates to delaying progression by roughly 5.3 months. The disease continues to advance during and after treatment.
Who is eligible to receive Leqembi?
Leqembi is approved for patients with early Alzheimer’s disease — meaning those with mild cognitive impairment or mild dementia with confirmed amyloid pathology. Genetic testing for ApoE4 status is recommended before starting treatment because patients carrying two copies of the ApoE4 gene face significantly higher risk of ARIA side effects. In Europe, the EMA restricted approval to patients with one or no copies of ApoE4.
What is ARIA and how common is it with Leqembi?
ARIA stands for Amyloid-Related Imaging Abnormalities, a class of side effects that includes brain swelling (ARIA-E, occurring in 13% of Leqembi patients vs. 2% on placebo) and brain microbleeds or hemorrhages (ARIA-H, occurring in 17% vs. 9% on placebo). Most cases are detected on routine MRI monitoring and resolve without symptoms, but serious ARIA requiring hospitalization occurred in 0.7% of patients.
How much does Leqembi treatment actually cost?
The drug’s annual list price is approximately $26,500, but total treatment costs — including required genetic testing, regular MRI monitoring, biweekly IV infusion sessions, and specialist care — are estimated at roughly $82,500 per year per patient. Most of this cost is borne by Medicare for eligible patients in the United States.
Can Leqembi be taken at home instead of through IV infusion?
As of August 2025, the FDA approved Leqembi Iqlik, a subcutaneous autoinjector for maintenance dosing that can be administered at home in about 15 seconds. A supplemental application for using the autoinjector as a starting dose is under Priority Review with a target FDA decision date of May 24, 2026. The at-home option has significantly fewer infusion-related reactions (less than 1% vs. 26% for IV).
Is Leqembi available outside the United States?
Availability varies significantly by country. The FDA fully approved Leqembi in July 2023. The European Medicines Agency initially rejected the drug in July 2024 but reversed course and approved it in November 2024, restricted to patients with one or no copies of ApoE4. In the UK, NICE approved lecanemab but did not make it available on the NHS due to cost-effectiveness concerns, meaning most British patients cannot access it through public healthcare.
